DK2820020T3 - PYRAZOLOTRIAZINE DERIVATIVES AS SELECTIVE CYCLIN DEPENDENT KINASE INHIBITORS - Google Patents
PYRAZOLOTRIAZINE DERIVATIVES AS SELECTIVE CYCLIN DEPENDENT KINASE INHIBITORS Download PDFInfo
- Publication number
- DK2820020T3 DK2820020T3 DK13707008.2T DK13707008T DK2820020T3 DK 2820020 T3 DK2820020 T3 DK 2820020T3 DK 13707008 T DK13707008 T DK 13707008T DK 2820020 T3 DK2820020 T3 DK 2820020T3
- Authority
- DK
- Denmark
- Prior art keywords
- isopropyl
- pyrazolo
- triazine
- amine
- benzyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12157751.4A EP2634190A1 (en) | 2012-03-01 | 2012-03-01 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| PCT/EP2013/054224 WO2013128028A1 (en) | 2012-03-01 | 2013-03-01 | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2820020T3 true DK2820020T3 (en) | 2016-07-04 |
Family
ID=47757629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13707008.2T DK2820020T3 (en) | 2012-03-01 | 2013-03-01 | PYRAZOLOTRIAZINE DERIVATIVES AS SELECTIVE CYCLIN DEPENDENT KINASE INHIBITORS |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9567345B2 (enExample) |
| EP (2) | EP2634190A1 (enExample) |
| JP (1) | JP6182549B2 (enExample) |
| KR (1) | KR101821452B1 (enExample) |
| CN (1) | CN104350054B (enExample) |
| AU (1) | AU2013224848B2 (enExample) |
| BR (1) | BR112014021189B1 (enExample) |
| CA (1) | CA2865946C (enExample) |
| DK (1) | DK2820020T3 (enExample) |
| ES (1) | ES2583231T3 (enExample) |
| HU (1) | HUE029264T2 (enExample) |
| IL (1) | IL234183A (enExample) |
| MX (1) | MX347359B (enExample) |
| RU (1) | RU2645347C2 (enExample) |
| SG (1) | SG11201405129RA (enExample) |
| WO (1) | WO2013128028A1 (enExample) |
| ZA (1) | ZA201406078B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| MX358346B (es) | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| EP3805218A1 (en) * | 2014-04-05 | 2021-04-14 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10131679B2 (en) | 2014-10-31 | 2018-11-20 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole compound |
| EP3268000B1 (en) * | 2015-03-09 | 2021-08-04 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
| AU2016281225B2 (en) | 2015-06-15 | 2020-10-15 | Ube Corporation | Substituted dihydropyrrolopyrazole derivative |
| CN107949563B (zh) * | 2015-06-24 | 2020-06-05 | 库洛维公司 | 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物 |
| JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
| CN106432249B (zh) * | 2016-09-30 | 2018-12-04 | 陕西科技大学 | 一类吡咯并[2，1-f][1，2，4]三嗪母核化合物的合成及其医药用途 |
| WO2019032720A1 (en) | 2017-08-09 | 2019-02-14 | Sanford Burnham Prebys Medical Discovery Institute | APELIN RECEPTOR AGONISTS AND METHODS OF USE |
| GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
| JP7133023B2 (ja) | 2018-01-17 | 2022-09-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｐｉ４ｋｉｉｉベータ阻害剤 |
| KR102966455B1 (ko) | 2018-04-11 | 2026-05-15 | 주식회사 큐리언트 | 사이클린 의존성 키나아제의 선택적 억제제로서의 피라졸로-트리아진 및/또는 피라졸로피리미딘 유도체 |
| MY207194A (en) | 2018-04-11 | 2025-02-05 | Qurient Co Ltd | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives |
| US12606561B2 (en) | 2018-04-11 | 2026-04-21 | Qurient Co., Ltd. | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors |
| US12022832B2 (en) | 2018-09-12 | 2024-07-02 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| US11517568B2 (en) | 2018-09-12 | 2022-12-06 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| EP3873462A4 (en) | 2018-11-01 | 2022-08-03 | Syros Pharmaceuticals, Inc. | CANCER TREATMENT METHODS IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLINE-DEPENDENT KINASE 7 (CDK7) |
| JP7530297B2 (ja) | 2018-11-14 | 2024-08-07 | Ｕｂｅ株式会社 | ジヒドロピロロピラゾール誘導体 |
| CN110101703B (zh) * | 2019-05-06 | 2021-06-11 | 暨南大学 | Cdk7抑制剂在制备溃疡性结肠炎或结肠癌药物的应用 |
| RU2713152C1 (ru) * | 2019-08-30 | 2020-02-04 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения хронической аллергической крапивницы на фоне описторхоза |
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| GB201918541D0 (en) * | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| CN110950871B (zh) * | 2019-12-25 | 2022-05-17 | 陕西师范大学 | 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用 |
| EP4263554A1 (en) * | 2020-12-21 | 2023-10-25 | JANSSEN Pharmaceutica NV | Tricyclic pyrimidines as cyclin-dependent kinase 7 (cdk7) inhibitors |
| US20250281495A1 (en) * | 2021-02-25 | 2025-09-11 | Icahn School Of Medicine At Mount Sinai | Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease |
| JP2024509864A (ja) * | 2021-03-09 | 2024-03-05 | ヤンセン ファーマシューティカ エヌ．ベー． | サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリジン |
| US20250042903A1 (en) * | 2021-06-17 | 2025-02-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Triazine inhibitors of cyclin-dependent kinases |
| WO2023001061A1 (en) * | 2021-07-17 | 2023-01-26 | Jingrui Biopharma Co., Ltd. | Cdk7 selective inhibitors as anticancer agents |
| EP4377312A1 (en) | 2021-07-29 | 2024-06-05 | Syngenta Crop Protection AG | Pesticidally active fused bicyclic heteroaromatic compounds |
| WO2023094310A1 (en) * | 2021-11-23 | 2023-06-01 | Origenis Gmbh | Pyrazolotriazine derivatives useful as cdk9 inhibitors |
| CN114181217B (zh) * | 2022-01-10 | 2022-12-27 | 陕西师范大学 | 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用 |
| WO2023175173A1 (en) * | 2022-03-18 | 2023-09-21 | Qurient Co., Ltd. | Cdk7 inhibitors for antiviral treatment |
| WO2024026486A2 (en) * | 2022-07-28 | 2024-02-01 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| EP4561552A4 (en) * | 2022-07-29 | 2026-07-15 | Cedilla Therapeutics Inc | CDK2 INHIBITORS AND THEIR METHODS OF USE |
| CN120712267A (zh) * | 2023-02-21 | 2025-09-26 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| IL144675A0 (en) * | 1999-02-01 | 2002-05-23 | Cv Therapeutics Inc | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| TW200536536A (en) * | 2004-02-25 | 2005-11-16 | Schering Corp | Pyrazolotriazines as kinase inhibitors |
| CZ302122B6 (cs) * | 2009-01-28 | 2010-10-20 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující |
| FR2943058B1 (fr) * | 2009-03-11 | 2011-06-03 | Centre Nat Rech Scient | Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique. |
| CZ302711B6 (cs) * | 2009-06-03 | 2011-09-14 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující |
-
2012
- 2012-03-01 EP EP12157751.4A patent/EP2634190A1/en not_active Withdrawn
-
2013
- 2013-03-01 KR KR1020147027812A patent/KR101821452B1/ko active Active
- 2013-03-01 EP EP13707008.2A patent/EP2820020B1/en active Active
- 2013-03-01 WO PCT/EP2013/054224 patent/WO2013128028A1/en not_active Ceased
- 2013-03-01 AU AU2013224848A patent/AU2013224848B2/en active Active
- 2013-03-01 DK DK13707008.2T patent/DK2820020T3/en active
- 2013-03-01 CN CN201380011917.5A patent/CN104350054B/zh active Active
- 2013-03-01 JP JP2014559259A patent/JP6182549B2/ja active Active
- 2013-03-01 MX MX2014010494A patent/MX347359B/es active IP Right Grant
- 2013-03-01 ES ES13707008.2T patent/ES2583231T3/es active Active
- 2013-03-01 RU RU2014139705A patent/RU2645347C2/ru active
- 2013-03-01 SG SG11201405129RA patent/SG11201405129RA/en unknown
- 2013-03-01 BR BR112014021189-2A patent/BR112014021189B1/pt active IP Right Grant
- 2013-03-01 US US14/381,146 patent/US9567345B2/en active Active
- 2013-03-01 HU HUE13707008A patent/HUE029264T2/en unknown
- 2013-03-01 CA CA2865946A patent/CA2865946C/en active Active
-
2014
- 2014-08-19 IL IL234183A patent/IL234183A/en active IP Right Grant
- 2014-08-19 ZA ZA2014/06078A patent/ZA201406078B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX347359B (es) | 2017-04-06 |
| US20150018329A1 (en) | 2015-01-15 |
| CA2865946A1 (en) | 2013-09-06 |
| MX2014010494A (es) | 2015-04-08 |
| BR112014021189A2 (enExample) | 2017-06-20 |
| US9567345B2 (en) | 2017-02-14 |
| SG11201405129RA (en) | 2014-09-26 |
| WO2013128028A8 (en) | 2014-10-02 |
| EP2820020A1 (en) | 2015-01-07 |
| KR101821452B1 (ko) | 2018-01-23 |
| JP2015511952A (ja) | 2015-04-23 |
| JP6182549B2 (ja) | 2017-08-16 |
| HUE029264T2 (en) | 2017-02-28 |
| WO2013128028A1 (en) | 2013-09-06 |
| KR20140131994A (ko) | 2014-11-14 |
| AU2013224848B2 (en) | 2017-06-29 |
| IL234183A (en) | 2016-11-30 |
| AU2013224848A1 (en) | 2014-08-28 |
| ES2583231T3 (es) | 2016-09-19 |
| EP2820020B1 (en) | 2016-04-06 |
| CN104350054B (zh) | 2017-06-13 |
| RU2645347C2 (ru) | 2018-02-21 |
| CN104350054A (zh) | 2015-02-11 |
| RU2014139705A (ru) | 2016-04-20 |
| EP2634190A1 (en) | 2013-09-04 |
| CA2865946C (en) | 2020-01-21 |
| HK1206014A1 (en) | 2015-12-31 |
| ZA201406078B (en) | 2016-08-31 |
| BR112014021189B1 (pt) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013224848B2 (en) | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors | |
| US9096608B2 (en) | Pharmaceutically active pyrazolo-triazine derivatives | |
| AU2022228101B2 (en) | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | |
| AU2018217488B2 (en) | Aminotriazolopyridines as kinase inhibitors | |
| CN107530329B (zh) | 用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物 | |
| AU2019211382B2 (en) | Aminopyrrolotriazines as kinase inhibitors | |
| DK2668184T3 (en) | DERIVATIVES OF AZAINDAZOL OR DIAZAINDAZOL TYPE AS MEDICATION | |
| CA2826464C (en) | Pharmaceutically active disubstituted triazine derivatives | |
| CA2895404A1 (en) | Bet-protein-inhibiting dihydropyridopyrazinones | |
| KR20160100407A (ko) | 신규한 글루타미나제의 저해제 | |
| WO2012117059A1 (en) | Pharmaceutically active disubstituted pyridine derivatives | |
| EP2550257A1 (en) | Pharmaceutically active disubstituted triazine derivatives | |
| WO2021175270A1 (zh) | 新型hpk1抑制剂及其制备方法和应用 | |
| AU2019237991B2 (en) | JAK inhibitors | |
| AU2022296371A1 (en) | Sulfoximide substituted indazole irak4 kinase inhibitor, preparation method therefor, and use thereof | |
| WO2017073743A1 (ja) | 三環性化合物 | |
| AU2005245536A1 (en) | Substituted azachinazolines having an antiviral action | |
| WO2024233554A1 (en) | Isoxazolidines as ripk1 inhibitors and use thereof | |
| HK1206014B (en) | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors | |
| CN101146797A (zh) | 用于治疗炎性疾病的作为p38map-激酶抑制剂的4-′2-(环烷基氨基)嘧啶-4-yl！-3-(苯基)-咪唑啉-2-酮衍生物 | |
| HK1193813B (en) | Pharmaceutically active disubstituted pyridine derivatives |